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Background. The IL23R gene has been identified as a susceptibility gene for inflammatory bowel disease (IBD) in the North
American population. The aim of our study was to test this association in a large German IBD cohort and to elucidate potential
interactions with other IBD genes as well as phenotypic consequences of IL23R variants. Methods. Genomic DNA from 2670
Caucasian individuals including 833 patients with Crohn’s disease (CD), 456 patients with ulcerative colitis (UC), and 1381
healthy unrelated controls was analyzed for 10 IL23R SNPs. Genotyping included the NOD2 variants p.Arg702Trp, p.Gly908Arg,
and p.Leu1007fsX1008 and polymorphisms in SLC22A4/OCTN1 (1672 CRT) and SLC22A5/OCTN2 (–207 GRC). Results. All
IL23R gene variants analyzed displayed highly significant associations with CD. The strongest association was found for the
SNP rs1004819 [P=1.92610
211; OR 1.56; 95 % CI (1.37–1.78)]. 93.2% of the rs1004819 TT homozygous carriers as compared to
78% of CC wildtype carriers had ileal involvement [P=0.004; OR 4.24; CI (1.46–12.34)]. The coding SNP rs11209026
(p.Arg381Gln) was protective for CD [P=8.04610
28; OR 0.43; CI (0.31–0.59)]. Similar, but weaker associations were found in UC.
There was no evidence for epistasis between the IL23R gene and the CD susceptibility genes CARD15 and SLC22A4/5.
Conclusion. IL23R is an IBD susceptibility gene, but has no epistatic interaction with CARD15 and SLC22A4/5. rs1004819 is the
major IL23R variant associated with CD in the German population, while the p.Arg381Gln IL23R variant is a protective marker
for CD and UC.
Citation: Glas J, Seiderer J, Wetzke M, Konrad A, To ¨ro ¨k H-P, et al (2007) rs1004819 Is the Main Disease-Associated IL23R Variant in German Crohn’s
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INTRODUCTION
Inflammatory bowel diseases (IBD) such as Crohn’s disease (CD)
and ulcerative colitis (UC) are chronic inflammatory disorders of
the gastrointestinal tract characterized by a perpetuated mucosal
immune response which is triggered by intestinal bacteria in
genetically susceptible individuals [1,2]. Since the identification of
CARD15 (encoding NOD2) as the first susceptibility gene for CD
in 2001 [3,4], several variants of proteins involved in bacterial
recognition were demonstrated to be associated with IBD or
certain IBD phenotypes [5,6,7,8,9,10,11].
Most recently, Duerr et al. [12] identified the IL23R gene
located on chromosome 1p31 as an IBD susceptibility gene in
a genome-wide association study testing 308,332 single nucleotide
polymorphisms (SNPs) in 547 non-Jewish ileal CD cases and 548
controls. Subsequent analyses by the same group confirmed these
findings in an independent Jewish CD cohort and in 883 nuclear
families [12]. In this study, the uncommon IL23R coding variant
rs11209026 (1142G.A; p.Arg381Gln) was associated with strong
protection against CD [12]. This was recently confirmed in
a British cohort [13] and for pediatric CD [14,15]. For nine other
variants located within the IL23R gene or in the intergenic area
with the adjacent IL12RB2 gene, Duerr et al. [12] demonstrated
associations with CD with p-values of ,0.0001. Some of these
variants also showed weaker associations with UC [12].
IL-23, a member of the IL-12 cytokine family, represents
a proinflammatory cytokine and is composed of the IL-23-specific
p19 subunit and a p40 subunit, which is also part of the IL-12
heterodimer.IL-23, mainlyproduced byactivated macrophages and
dendritic cells (DCs), activates Th17 cells which differentiate under
the influence of the cytokines IL-6 and TGF-b [16]. Very recent
studies indicate also a role for IL-21 in this process [17,18,19]. In
Th17 cells, the transcription factor RORct activates the expression
of proinflammatory Th17 cytokines such as IL-17A, IL-17F and IL-
22. In contrast, IL-12 induces the differentiation of naive CD4+ T
cells into IFN-c producing Th1 cells through activation of STAT4.
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a downstream transcription factor, T-bet, which enhances the
expression of genes specific to Th1 cells. Th1 cells promote a cell-
mediated immune response to intracellular pathogens, while IL-4-,
IL-5- and IL-13-producing Th2 cells promote a humoral immune
response to extracellular pathogens. Similarly, there is increasing
evidence for the IL-23/IL-17 axis as a key pathway in the
development of chronic inflammation and in host defense against
bacterial infection, promoting local tissue inflammation by stimulat-
ing T cells, macrophages and fibroblasts as well as endothelial and
epithelial cells to produce proinflammatory cytokines, metallopro-
teinases, and chemokines (reviewed in Ref.[20]). Recent studies
demonstrated a critical role for the IL-23/IL-17 pathway in T-cell
mediated colitis in different mouse models [21,22,23], in tumour
immunity as demonstrated in human tumor tissues and cancer cell
lines as well as in knockout mice [24,25], and in the development of
autoimmune diseases including autoimmune encephalomyelitis in
a mouse model [26] and in patients with multiple sclerosis [27]. A
very recent study demonstrated that monoclonal antibodies (mAb)
directed against IL-23 reverse active colitis in a T cell-mediated
model of murine colitis [28].
The strong expression of IL-23 in ileal DCs in a mouse model
and human CD [20,22,29] and the recent findings of the genome-
wide association study [12] suggest that the IL-23/IL-23R
cytokine receptor system is also involved in the pathogenesis of
CD. Interestingly, IL-23 secretion in ileal DCs is driven by the
intestinal bacterial microflora [30], and we recently demonstrated
that ileal DCs may actively sample luminal bacteria via dendrites
reaching the intestinal lumen [31]. However, only myeloid DCs
and not plasmacytoid DCs secreted IL-23 upon stimulation with
various toll-like receptor (TLR) ligands [32]. Increased IL-23
secretion has been shown in antigen-presenting cells (APCs)
derived from lamina propria mononuclear cells of CD patients
which could be down-regulated by anti-IL-12p40 mAb treatment
[29]. In contrast, APCs from UC patients produced only baseline
levels of IL-23 [29]. Moreover, a very recent study demonstrated
in a mouse model that IL-23 producing DCs participate in
intestinal granuloma formation [33] further pointing to a role for
this cytokine in the pathogenesis of CD.
Since replication of genome-wide association findings in
populations with different genetic background is essential to
confirm disease susceptibility genes [34] and in order to clarify
the phenotypic consequences of the different IL23R variants in
IBD, we performed a detailed genotype-phenotype analysis in
a large German IBD cohort (CD: n=833; UC: n=456; controls:
n=1289) by analyzing all 10 IL-23R variants for which significant
linkage to CD has been demonstrated in the study by Duerr et al.
[12]. In addition, we tested for epistasis of IL23R variants with
CARD15 gene variants [3,4,35], and SNPs in SLC22A4 (solute
carrier family 22, member 4), encoding the organic cation
transporter 1 (OCTN1), and in SLC22A5, encoding OCTN2
[8,10,36]. Since these gene variants are proven CD susceptibility
genes associated with distinct phenotypic characteristics [10,37,38],
our aim was to investigate potential interactions with IL23R
variants including epistatic effects on certain disease phenotypes. In
a detailed genotype-phenotype analysis, we also analyzed the
effects of IL23R variants on specific CD and UC disease subtypes.
METHODS
Study population
The study population (n=2670) was comprised of 1289 IBD
patients of Caucasian origin including 833 patients with CD, 456
patients with UC, and 1381 healthy, unrelated controls. Written,
informed consent was obtained from all patients. The study was
approved by the local Ethics committee and adhered to the Ethical
Principles for Medical Research Involving Human Subjects of the
Helsinki Declaration (http://www.wma.net/e/policy/b3.htm).
Demographic and clinical data (behaviour and location of IBD,
disease-related complications, need for surgery or immunosup-
pressive therapy) were recorded by analysis of patient charts and
a detailed questionnaire including an interview at time of
enrolment. The demographic characteristics of the IBD study
population were collected blind to the results of the genotype
analyses and are summarized in Table 1. The diagnosis of CD or
UC was determined according to established guidelines based on
endoscopic, radiological, and histopathological criteria [39].
Patients with CD were assessed according to the Montreal
classification [40] based on the age at diagnosis (A), location (L),
and behaviour (B) of disease. In patients with UC, anatomic
location was also based on the Montreal classification, using the
criteria ulcerative proctitis (E1), left-sided UC (distal UC; E2), and
extensive UC (pancolitis; E3). Patients with indeterminate colitis
were excluded from the study.
DNA extraction and genotyping of the IL23R
variants
Genomic DNA was isolated from peripheral blood leukocytes by
standard procedures using the DNA blood mini kit from Qiagen
(Hilden, Germany). The 10 IL23R SNPs (rs1004819, rs7517847,
rs10489629, rs2201841, rs11465804, rs11209026=p.Arg381Gln,
rs1343151, rs10889677, rs11209032, rs1495965), for which
significant associations with CD were found in a previous study
[12], were genotyped by PCR and melting curve analysis using
a pair of fluorescence resonance energy transfer (FRET) probes in
a LightCyclerH 480 Instrument (Roche Diagnostics, Mannheim,
Germany). The donor fluorescent molecule (fluorescein) at the 39-
end of the sensor probe is excited at its specific fluorescence
excitation wavelength (533 nm) and the energy is transferred to the
acceptor fluorescent molecule at the 59-end of the anchor probe
(LightCycler Red 610, 640, or 670). The specific fluorescence
signal emitted by the acceptor molecule is detected by the
LightCyclerH 480 Instrument. The sensor probe matches exactly
to one allele of each SNP, preferentially to the less common allele,
whereas, in the case of the other allele, there is a mismatch
resulting in a lower melting temperature. The total volume of the
PCR was 5 ml containing 25 ng of genomic DNA, 16Light Cycler
480 Genotyping Master (Roche Diagnostics), 2.5 pmol of each
primer, and 0.75 pmol of each FRET probe (TIB MOLBIOL,
Table 1. Demographic characteristics of the IBD study
population.
......................................................................
CD (n=833) UC (n=456)
Gender
Male (%) 46.0% 51.8%
Female (%) 54.0% 48.2%
Age (yr)
Mean6SD 39.5618.7 41.5620.4
Range 10–80 7–85
Age at diagnosis (yr)
Mean6SD 27.9616.4 31.8618.5
Range 7–71 9–81
doi:10.1371/journal.pone.0000819.t001
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PLoS ONE | www.plosone.org 2 September 2007 | Issue 9 | e819Berlin, Germany). Amplification included an initial denaturation
step (95uC for 10 min) followed by 45 cycles (95uC for 10 sec,
primer annealing temperature as given in table S1 for 10 sec,
72uC for 15 sec). The melting curve analysis was comprised of an
initial denaturation step (95uC for 1 min), a step rapidly lowering
the temperature to 40uC and holding for 30 sec, and a heating
step slowly increasing the temperature up to 80uC and
continuously measuring the fluorescence intensity (1 acquisition/
uC). The results of the melting curve analysis were confirmed by
analyzing samples representing all possible genotypes using
sequence analysis. All sequences of primers and FRET probes
and primer annealing temperatures used for genotyping and for
sequence analysis are given in the Supplementary data (Tables S1
and S2).
Genotyping of the CARD15 and OCTN1/2 variants
Genotyping of the three common NOD2 variants p.Arg702Trp
(rs2066844), p.Gly908Arg (rs2066847), and p.Leu1007fsX1008
(rs2066847) was performed as described previously [9]. In
addition, the 1672 CRT SNP in SLC22A4 (rs1050152) encoding
OCTN1 and the –207 GRC SNP (rs2631367) in SLC22A5
encoding OCTN2 were investigated by restriction fragment length
polymorphism analysis as described previously [10] or by melting
curve analysis using FRET probes (primer and probe sequences
are available on request).
Statistical analyses
Each genetic marker was tested for Hardy-Weinberg equilibrium
in the control population. For comparison between categorical
variables, Fisher’s exact test or x
2 test was used where appropriate.
Single-marker allelic tests were performed with Pearson’s x
2 test.
Student’s t-test was applied for quantitative variables. All tests
were two-tailed, considering p-values ,0.05 as significant. Odds
ratios were calculated for the minor allele at each SNP. For
multiple comparisons, Bonferroni correction was applied. Data
were evaluated by using the SPSS 13.0 software (SPSS Inc.,
Chicago, IL, USA) and R-2.4.1. (http://cran.r-project.org).
Interactions between different polymorphisms were tested
using logistic regression in R testing using the number of minor
alleles as predictor variable thus implementing an Armitage test
of trend.
RESULTS
Frequency distribution of IL23R genotypes and their
role in IBD susceptibility
In all three subgroups (CD, UC, and controls), the genotype
frequencies of the 10 IL23R SNPs were in accordance with the
Hardy-Weinberg equilibrium. All IL23R gene variants displayed
highly significant associations with CD. The P-values ranged from
4.36610
25 to 1.92610
211 (Table 2). The distribution of wildtype,
heterozygous and homozygous carriers of each IL23R variant in
CD and UC compared to controls is given in Table S3. In CD,
the strongest association was found for the SNP rs1004819
[P=1.92610
211; OR 1.56; 95 % CI (1.37–1.78)]. The allele
frequencies for the SNP rs11209026 (p.Arg381Gln), which
displayed the strongest association in the study of Duerr et al.
[12], showed also highly significant differences between CD
patients and controls in our study. The minor allele frequency was
0.030 in CD as compared to 0.068 in the controls [P=8.04610
28;
OR 0.43; 95 % CI (0.31–0.59); Table 2], suggesting a protective
effect against CD. By combining both SNPs in a logistic regression
analysis, we were able to demonstrate independent effects on CD
susceptibility. An additional independent effect could also be
shown for rs7517847, while the other seven IL23R SNPs were not
independently disease-associated.
In contrast to CD, the associations of IL23R SNPs with
susceptibility to UC were markedly weaker. However, with the
exception of rs11465804 and rs11209032, all other IL23R variants
were significantly associated with UC in the univariate analysis
(Table 2). For these eight SNPs, the odds ratios differentiating
between protection against UC (OR,1.0) or increased UC
susceptibility (OR.1.0), were very similar to those observed for
CD (Table 2), suggesting overall similar disease-modifying effects of
the different IL23R variants on CD and UC. The most strongly UC-
associated SNP was rs7517847 [P=3.78 610
24;O R =0 . 7 6 ;9 5%
CI (0.65–0.88)]. Similar to CD, the frequency of the SNP
rs11209026 (p.Arg381Gln) was significantly decreased in UC
patients compared to the controls, although this association was
much weaker than in CD [P=3.61 610
22;O R = 0 . 7 0 ;9 5%C I
(0.50–0.98)] in the univariate analysis (Table 2). While the minor
allele of these two IL23R variants protected against UC, the minor
allele of rs1004819 was associated with UC in the univariate analysis
[P=3.81610
23; OR=1.27; 95 % CI (1.08–1.50)]. Comparing only
Table 2. Associations of IL23R gene markers in CD and UC case-control association studies.
..................................................................................................................................................
Gene marker
Minor
allele Crohn’s disease n=833 Ulcerative colitis n=456
Controls
n=1381
MAF p value OR [95 % CI] MAF p value OR [95 % CI] MAF
rs1004819 T 0.360 1.92610
211 1.56 [1.37–1.78] 0.314 3.81610
23 1.27 [1.08–1.50] 0.265
rs7517847 G 0.356 1.86610
29 0.68 [0.60–0.77] 0.381 3.78610
24 0.76 [0.65–0.88] 0.448
rs10489629 G 0.390 1.05610
26 0.73 [0.65–0.83] 0.413 5.59610
23 0.81 [0.69–0.94] 0.465
rs2201841 C 0.348 1.90610
28 1.46 [1.28–1.66] 0.307 2.11610
22 1.21 [1.03–1.43] 0.268
rs11465804 G 0.033 4.13610
25 0.53 [0.39–0.72] 0.047 1.27610
21 0.77 [0.54–1.08] 0.061
rs11209026 A 0.030 8.04610
28 0.43 [0.31–0.59] 0.049 3.61610
22 0.70 [0.50–0.98] 0.068
rs1343151 T 0.288 4.36610
25 0.76 [0.67–0.87] 0.312 4.81610
22 0.85 [0.72–1.00] 0.347
rs10889677 A 0.346 9.69610
29 1.47 [1.29–1.68] 0.312 5.17610
23 1.26 [1.07–1.49] 0.264
rs11209032 A 0.367 7.29610
28 1.43 [1.25–1.62] 0.319 8.29610
22 1.15 [0.98–1.36] 0.288
rs1495965 G 0.497 3.74610
26 1.33 [1.18–1.51] 0.468 2.41610
22 1.29 [1.02–1.38] 0.425
Minor allele frequencies (MAF), allelic test P-values, and odds ratios (OR, shown for the minor allele) with 95% confidence intervals (CI) are depicted for both the CD and
UC case-control cohorts.
doi:10.1371/journal.pone.0000819.t002
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PLoS ONE | www.plosone.org 3 September 2007 | Issue 9 | e819SNPs with ORs.1.0 in this analysis, rs1004819 was the most
strongly UC-associated IL23R variant, similar to our results in CD.
However, stepwise forward logistic regression analysis revealed only
rs7517847 as an independent risk factor for UC.
Associations between IL23R genotype and IBD
phenotype
Having confirmed that IL23R is an IBD susceptibility gene also in
the German population, we next investigated potential phenotypic
consequences of IL23R variants in a well-characterized subgroup of
patients from the Munich IBD center. Table 3 summarizes
the disease characteristics of CD patients depending on the
rs11209026 (p.Arg381Gln) IL23R genotype status. In CD patients
with different rs11209026 (p.Arg381Gln) genotypes, there were no
differences in the frequency of disease characteristics such as age of
onset, disease behaviour, disease location as defined by the Montreal
classification [40], extraintestinal involvement, and other complica-
tions of CD such as incidence of stenoses, fistulas, abscess formation,
or the use of immunosuppressive agents (Table 3), although there
was a trend towards less surgical interventions in carriers of the A
allele of the p.Arg381Gln variant, which, however, did not reach
statistical significance [P=0.067; OR 0.39; CI (0.15–1.05)]. A
subgroup analysis based on the type of surgery (e.g., stricturoplasty,
ileocecal resection, fistulectomy, colectomy) did not demonstrate
significant associations to a certain type of surgical intervention nor
to a certain cause of surgery, e.g., ileal stenosis (data not shown).
However, this analysis was limited by the fact that the subgroup
analyzed for phenotypic consequences did not contain AA
homozygous carriers of the rs11209026 (p.Arg381Gln) variant.
Analyzing the phenotypic contribution of the rs1004819 IL23R
variant, which had overall the most significant association with
CD, there was an increased incidence of ileal involvement in TT
homozygous carriers (93.2%) compared to CC wildtype carriers
(78.0%) [P=0.004; OR 4.24; CI (1.46–12.34); Table 4] which,
however, lost significance after Bonferroni correction. Similarly,
there was an increased incidence of stenosis in rs1004819 TT
homozygotes compared to carriers of the CC genotype [(74.6% vs.
59.6%; P=0.045; OR 1.99; CI (1.04–3.82); Table 4] which also
did not fulfill the criteria of significance after Bonferroni
correction. Moreover, the variant rs7517847, for which we
demonstrated an association with UC in the stepwise logistic
regression analysis, was not associated with any specific disease
subtype (data not shown).
Table 3. Association between IL23R p.Arg381Gln (rs11209026) genotype and CD disease characteristics in the subcohort of the
Munich IBD center (n=452) for which detailed phenotypic data based on the Montreal classification [40] were available.
..................................................................................................................................................
IL23R p.Arg381Gln (rs11209026) genotype status (1) GG (2) GA* (1) vs. (2) p value (1) vs. (2) OR (95% CI)
(n=452) (n=430) (n=22)
Male sex (n=449) 46.1% 45.2% 1.000 0.97 (0.52–1.81)
Age at diagnosis (yr) (n=449)
Mean6SD 27.8616.3 31.6618.2 0.207 N/A
Range 7–71 12–56
Disease duration (yr) (n=444)
Mean6SD 12.267.7 9.466.6 0.200 N/A
Range 0–44 3–32
Age at diagnosis (n=444)
#16 years (A1) 12.1% 4.5% 0.495 0.35 (0.05–2.63)
17–40 years (A2) 74.9% 72.7% 0.804 0.90 (0.34–2.34)
.40 years (A3) 13.0% 22.7% 0.200 1.96 (0.70–5.53)
Location (n=449)
Terminal ileum (L1) 12.9% 13.6% 1.000 1.07 (0.31–3.73)
Colon (L2) 17.1% 27.3% 0.248 1.82 (0.69–4.80)
Ileocolon (L3) 69.3% 59.1% 0.347 0.64 (0.27–1.53)
Upper GI (L4) 0.7% 0.0% 1.000 N/A
Behaviour
1 (n=447)
Non-stricturing, Non-penetrat. (B1) 21.6% 27.3% 0.596 1.36 (0.52–3.57)
Stricturing (B2) 25.6% 13.6% 0.312 0.46 (0.13–1.58)
Penetrating (B3) 52.7% 59.1% 0.663 1.30 (0.54–3.10)
Use of immunosuppressive agents
2 (n=286) 83.6% 70.6% 0.183 0.47 (0.16–1.40)
Surgery because of CD
3 (n=439) 52.0% 30.0% 0.067 0.39 (0.15–1.05)
Fistulas (n=450) 52.3% 59.1% 0.663 1.31 (0.55–3.14)
Stenosis (n=452) 63.0% 54.5% 0.499 0.70 (0.30–1.67)
For each variable, the number of patients included is given.
*In this subgroup, there were no AA homozygous carriers for the genotype-phenotype analysis available.
1Disease behaviour was defined according to the Montreal classification [40]. A stricturing disease phenotype was defined as presence of stenosis without penetrating
disease. The diagnosis of stenosis was made surgically, endoscopically, or radiologically (using MRI enteroclysis).
2Immunosuppressive agents included azathioprine, 6-mercaptopurine, 6-thioguanin, methotrexate, and/or infliximab.
3Only surgery related to CD-specific problems (e.g. fistulectomy, colectomy, ileostomy) was included.
doi:10.1371/journal.pone.0000819.t003
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PLoS ONE | www.plosone.org 4 September 2007 | Issue 9 | e819Analysis for epistasis between IL23R, CARD15 and
SLC22A4/5 genes in CD patients
Finally, we analyzed potential evidence for epistasis of IL23R
variants with the other three replicated IBD susceptibility genes
CARD15 [3,4,35], SLC22A4, and SLC22A5 [8,10,36] including
their effects on overall disease susceptibility and phenotype. In all
three subgroups (CD, UC, and controls), the frequencies of the
analyzed NOD2 variants (p.Arg702Trp, p.Gly908Arg,
p.Leu1007fsX1008) and of the SNPs in SLC22A4 (1672 CRT)
and in SLC22A5 (–207 GRC) were in accordance with the Hardy-
Weinberg equilibrium. Except from SLC22A5 (–207 GRC), all
SNPs were highly associated with CD but not with UC (Table 5).
No evidence for epistasis between these three CD susceptibility
genes and IL23R variants was found in CD and UC. None of the
P-values found was significant after correction for multiple testing;
the lowest P-value for CD was 0.147 for the interaction between
rs11209026 and NOD2 mutation status with an associated OR of
1.33 [CI (0.92–1.91)]. There was evidence for epistatic gene-gene
interactions regarding several phenotypic disease characteristics
which are summarized in the Supplementary Data (Table S4 and
S5). However, given the large number of interactions analyzed
(n=364), none of these P values remained significant at a P level of
,0.05 after Bonferrroni correction.
DISCUSSION
The present study confirms the previously described association of
IL23R gene variants with CD in a large German IBD patient
cohort and demonstrates a particular role for the rs1004819
variant in the pathogenesis of CD in German patients. It is the first
study analyzing for potential epistasis between IL23R variants and
the three other previously described CD susceptibility genes
CARD15, SLC22A4, and SLC22A5. Our results also verify the
previously identified role of rs11209026 (p.Arg381Gln) as a pro-
tective variant in CD [12]. The greatest influence on the disease
risk for CD was seen in homozygous carriers of the minor allele of
the rs1004819 and rs11209026 (p.Arg381Gln) gene variants with
an odds ratio of 2.46 and 0.41, respectively, compared to healthy
controls, demonstrating opposing effects of these two SNPs on CD
susceptibility. By confirming the results obtained by Duerr et al.
[12], our study supports the validity of chip-based technologies for
the rapid identification of disease susceptibility genes in genome-
wide association studies.
The identification of rs1004819 as an independent major CD
susceptibility variant in our patient cohort contrasts with the data
published by Duerr et al. [12] and those of a related study with an
overlapping North American study population [41], in which
rs7517847 had the strongest association to CD. In a very recent
Table 4. Associations between IL23R SNP rs1004819 genotypes and CD disease characteristics in the subcohort of the Munich IBD
center (n=457) for which detailed phenotypic data based on the Montreal classification [40] were available.
..................................................................................................................................................
IL23R rs1004819 genotype status (1) CC (2) CT (3) TT (1) vs. (2) p value (1) vs. (3) p value (2) vs. (3) p value
(n=457) (n=193) (n=205) (n=59)
Male sex (n=457) 48.7% 45.9% 39.0% 0.616 0.233 0.375
Age at Diagnosis (yr) (n=413)
Mean6SD 27.3612.5 28.5614.5 28.1615.8 0.297 0.697 0.833
Range 11–65 11–71 7–71
Disease duration (yr) (n=413)
Mean6SD 11.968.6 12.068.6 13.4610.7 0.889 0.476 0.515
Range 2–35 0–33 3–44
Age at diagnosis (n=413)
#16 years (A1) 12.8% 8.3% 13.5% 0.175 1.000 0.284
17–40 years (A2) 76.7% 76.2% 71.2% 1.000 0.465 0.460
.40 years (A3) 10.6% 15.5% 15.4% 0.211 0.334 1.000
Location (n=451)
Terminal ileum (L1) 12.0% 13.4% 13.6% 0.762 0.821 1.000
Colon (L2) 21.5% 16.4% 6.8% 0.245 0.011,OR 0.27 CI 0.09–0.78 0.080
Ileocolon (L3) 66.0% 69.2% 79.7% 0.519 0.053 0.140
Upper GI (L4) 0.5% 1.0% 0.0% 1.000 1.000 1.000
Any ileal involvement (L1+L3) 76.4% 82.6% 93.2% 0.135 0.004,OR 4.24 CI 1.46–12.34 0.060
Behaviour
1 (n=452)
Non-stricturing, Non-penetrat. (B1) 22.5% 21.3% 18.6% 0.808 0.591 0.719
Stricturing (B2) 26.2% 22.3% 35.6% 0.410 0.187 0.043, OR 1.93 CI
1.03–3.61
Penetrating (B3) 51.3% 56.4% 45.8% 0.313 0.552 0.181
Surgery because of CD
3 (n=441) 48.1% 50.3% 62.7% 0.683 0.054 0.103
Fistulas (n=455) 50.8% 56.3% 45.8% 0.314 0.553 0.183
Stenosis (n=457) 59.6% 59.6% 74.6% 0.607 0.045,OR 1.99 CI 1.04–3.82 0.090
Significant P-values are given in bold letters including corresponding odds ratios (OR) and 95% confidence intervals (CI). However, none of these P-values remained
significant after Bonferroni correction (P.0.05). For each variable, the number of patients with a complete data set is given. Footnotes: See legend of Table 3 for
detailed explanation.
doi:10.1371/journal.pone.0000819.t004
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PLoS ONE | www.plosone.org 5 September 2007 | Issue 9 | e819British study, in contrast, the strongest association to CD was
found for rs11209026 (p.Arg381Gln) [13], while another genome-
wide association study from Belgium identified (in addition to
rs11209026) rs11465804 as the strongest CD-associated marker
[42]. Overall, these studies confirm IL23R as a CD susceptibility
gene, but demonstrate differences for certain IL23R variants
regarding the strength of their disease-modifying effect in different
populations.
Importantly, our study also revealed similar, but markedly
weaker associations of several IL23R SNPs with UC, suggesting
that certain IL23R variants may also contribute to the pathogen-
esis of UC which is not the case for the other main CD
susceptibility gene CARD15. As these SNPs were not completely
consistent to those found in the previous genome-wide study [12],
it has to be acknowledged that the present study included only
cases with sporadic UC, whereas Duerr et al. [12] investigated
familial UC.
A detailed genotype-phenotype analysis revealed weak associa-
tions of the IL23R rs1004819 variant with ileal involvement
(P=0.004) and stenoses (P=0.045) in carriers of the TT genotype
compared to carriers of the CC wildtype genotype. However, both
associations did not fulfill significance criteria after Bonferroni
correction. Nevertheless, the prevalence of ileal involvement in
carriers of the TT genotype of the rs1004819 variant (93.2%) was
remarkable high. Given that the original study by Duerr et al. [12]
analyzed only ileal cases of CD, it has been assumed that some of
the IL23R variants may predispose to an ileal disease phenotype.
However, a very recent British study could not identify a certain
disease phenotype associated with IL23R variants but the strength
of the association between CD and the rs1004819 variant was
almost 1000fold weaker than in our study group (P=1.1610
28 vs.
1.92610
211) [13] which may partly explain the different results of
these two genotype-phenotype analyses. It has to be acknowledged
that our genotype-phenotype analysis was limited to patients with
detailed phenotype status available which were all part of the
Munich IBD center patient population. Moreover, none of the
patients included in the phenotype analysis was homozygous for
the AA genotype of the rs11209026 variant. Therefore, it can not
be excluded that larger multicenter trials or metaanalyses may
reveal a certain disease phenotype associated with IL23R variants.
Interestingly, IL23R was also identified as a disease-associated
gene in other chronic inflammatory diseases. The rs10489629
variant was found to be associated with chronic periodontitis (Glas
et al., unpublished data), while in psoriasis, a predisposing
haplotype including the p.Arg381Gln variant (rs11209026) has
been described [43]. In both CD [44] and psoriasis [45], treatment
with an anti-p40 IL-12/23 antibody demonstrated therapeutic
efficacy. Therefore, IL23R potentially represents a susceptibility
gene and therapeutic target in various chronic inflammatory
diseases. However, the degree and the variety of associated SNPs
may differ in the different diseases. Possibly, IL23R variants result
in alternative mRNA splicing, leading to corresponding IL-23R
isoforms [46] with different tissue distributions. Functional studies
will be necessary to clarify this issue.
Supporting the results of the first pilot study in human CD [44],
neutralizing antibodies to the p40 subunit, which block both IL-12
and IL-23, suppressed established chronic intestinal inflammation
in an animal model of CD [47,48]. Studies in knockout mice and
the efficacy of antibodies against the IL-23-specific p19 subunit
suggest that IL-23 rather than IL-12 drives chronic intestinal
inflammation [23,28]. The T-cell response activated by IL-23 is
attenuated by SOCS3, which acts as a feedback inhibitor to
regulate Th17 cells [49]. Interestingly, we recently demonstrated
activation of STAT3 by IL-22 [50,51], which is also produced in
Th17 cells [52], and attenuation of IL-22 signaling by SOCS3
overexpression [51]. Although selective targeting of IL-23 is now
emerging as an attractive concept, p19-deficient mice are highly
susceptible to T cell–mediated colitis [22].
Despite the successful proof of principle for the applicability of
genome-wide association studies in the genetics of complex
diseases, the contribution of certain IL23R variants to CD or
UC is not sufficiently strong to explain the genetic background of
IBD on its own. Other candidate genes are likely to be involved
and recent genome wide scans suggest also ATG16L1 [41,42,53],
PHOX2B, NCF4, FAM92B [41], and a region modulating PTGER4
expression [42] as CD susceptibility genes, but further confirma-
tory studies are necessary. In contrast, a multitude of studies
demonstrated that certain NOD2 variants, particularly
p.Arg702Trp, p.Gly908Arg, and p.Leu1007fsX1008, are associ-
ated with CD, but not with UC. We and others demonstrated
a strong association with an ileal disease phenotype particularly for
the p.Leu1007fsX1008 variant [37,38]. Interestingly, in this study,
p.Leu1007fsX1008 was the most strongly CD-associated gene
variant in a combined multivariate analysis (Supplementary Data,
Table S6). The other CD susceptibility gene repeatedly confirmed
is located within the IBD5 locus and most likely represented by
certain OCTN variants [8,10]. We therefore also investigated
possible interactions of IL23R variants with these IBD susceptibil-
ity genes. We could not demonstrate an epistatic interaction
between IL23R variants and the analyzed variants in the SLC22A4,
SLC22A5 and CARD15 genes on IBD susceptibility but demon-
strated for some gene variants an epistatic influence on certain
disease characteristics. However, these interactions lost signifi-
cance after Bonferroni correction.
In conclusion, we confirmed the association of IL23R with IBD.
In addition to the protective IL23R variant rs11209026
(p.Arg381Gln), we identified rs1004819 as independent risk factor
for developing CD and UC in the German population which may
also contribute to an ileal disease phenotype in CD. A combined
analysis of variants in three other CD susceptibility genes
(CARD15, SLC22A4, SLC22A5) found no evidence for epistasis to
IL23R regarding CD susceptibility.
Table 5. Association of CARD15, SLC22A4 and SLC22A5 variants
with CD (n=833) and UC (n=456) compared to the control
population (n=1381).
......................................................................
SNP P value OR 95% CI
Crohn’s disease (n=833)
CARD15 R702W 4.02610
25 1.92 1.39–2.64
CARD15 G908R 9.43610
23 1.81 1.14–2.87
CARD15 1007fs 2.75610
215 3.68 2.54–5.35
Any CARD15 variant 2.41610
215 2.89 2.15–3.63
SLC22A4 (1672 CRT) 1.23610
22 1.15 1.03–1.28
SLC22A5 (–207 GRC) 7.71610
22 0.87 0.74–1.02
Ulcerative colitis (n=456)
CARD15 R702W 0.932 1.02 0.66–1.58
CARD15 G908R 0.704 0.89 0.47–1.66
CARD15 1007fs 0.174 0.64 0.34–1.23
Any CARD15 variant 0.320 0.83 0.58–1.19
SLC22A4 (1672 CRT) 0.573 1.04 0.91–1.18
SLC22A5 (–207 GRC) 0.976 1.00 0.83–1.21
OR: odds ration; 95% CI: 95% confidence interval.
doi:10.1371/journal.pone.0000819.t005
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